• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Scholar Rock Holding Corporation

    4/28/25 8:42:04 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SRRK alert in real time by email
    DEFA14A 1 tm2513330d2_defa14a.htm DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 14A INFORMATION

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

    Filed by the Registrant x
    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨ Preliminary Proxy Statement
    ¨ Confidential, for Use of the SEC Only (As Permitted by Rule 14a-6(e)(2))
    ¨ Definitive Proxy Statement
    x Definitive Additional Materials
    ¨ Soliciting Material Pursuant to § 240.14a-12

     

    SCHOLAR ROCK HOLDING CORPORATION

    (Name of Registrant as Specified in Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    x No fee required.
    ¨ Fee paid previously with preliminary materials.
    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

    SUPPLEMENT TO DEFINITIVE PROXY STATEMENT

    FOR THE SPECIAL MEETING OF STOCKHOLDERS

    TO BE HELD ON MAY 22, 2025

    EXPLANATORY NOTE

     

    On April 11, 2025, Scholar Rock Holding Corporation (the “Company”), filed with the Securities and Exchange Commission (the “SEC”) a definitive proxy statement on Schedule 14A (the “Proxy Statement”) relating to the Company’s Annual Meeting of Stockholders (the “Annual Meeting”) to be held on May 22, 2025 at 12:00 noon Eastern Time. As previously disclosed, the board of directors of the Company has fixed the close of business on March 26, 2025, as the record date (the “Record Date”) for determining stockholders entitled to vote at the Annual Meeting and at any adjournment(s) or postponement(s) thereof. Capitalized terms used in this supplement to the Proxy Statement (the “Supplement”) without definition have the same meanings as set forth in the Proxy Statement.

     

    WITHDRAWAL OF NOMINEE FOR ELECTION TO THE BOARD OF DIRECTORS

     

    As noted in the Current Report on Form 8-K filed by the Company on April 28, 2025 (the “Form 8-K”), subsequent to the filing of the Proxy Statement, Jay T. Backstrom transitioned from the Company’s Chief Executive Officer and President, to Senior Advisor effective as of April 27, 2025, and resigned as a director of the Board and all committees thereto, effective as of April 27, 2024. Following Dr. Backstrom’s resignation, the Board has reduced its size to nine directors.

     

    Among other items in the Proxy Statement, the Company asked its stockholders to vote on the election of three director nominees to the Board, which included Dr. Backstrom. In connection with his resignation from the Board, Dr. Backstrom’s name has been withdrawn as a director nominee for re-election to the Board at the Annual Meeting. The Board has not nominated a substitute director for election at the Annual Meeting in lieu of Dr. Backstrom, and accordingly, two director nominees will be considered for election at the Annual Meeting.

     

    The Board continues to recommend a vote “FOR” each of the remaining two director nominees: Srinivas Akkaraju, M.D., Ph.D. and M.P.H. and Joshua Reed, each of whom are current members of the Board.

     

    In connection with Dr. Backstrom’s departure, the Board appointed David Hallal, current Chairman of the Board, as the Company’s Chief Executive Officer effective as of April 27, 2025. The Board also appointed Akshay Vaishnaw, a current member of the Board, as President of Research & Development for the Company, R. Keith Woods as the Company’s Chief Operating Officer and Vikas Sinha as the Company’s Chief Financial Officer in each case effective on April 27, 2025. For more information, please see the Form 8-K.

     

    SUBMISSION OF PROXIES; VOTING

     

    Due to Dr. Backstrom’s departure, Dr. Backstrom will no longer serve as a proxy holder at the Annual Meeting. Junlin Ho was also designated by the Board to vote the shares represented by proxy at the Annual Meeting, with the power to appoint her substitute. As set forth in the Proxy Statement, Ms. Ho will vote the shares represented by each valid and timely received proxy in accordance with the stockholder’s instructions, or if no instructions are specified, in accordance with the recommendations of the Board as described in the Proxy Statement. If any other matter properly comes before the Annual Meeting, Ms. Ho will vote on that matter in her discretion.

     

    If you have already voted, you are not required to take any action, unless you would like to change your vote. Your previously submitted proxy will be voted at the Annual Meeting in the same manner as you instructed previously. If you have already voted and submit a new proxy, your new proxy will supersede the one you previously submitted.

     

    This Supplement should be read in conjunction with the Proxy Statement. Except as specifically amended or supplemented by the information contained herein, this Supplement does not otherwise modify, amend or supplement the Proxy Statement, and the information contained in the Proxy Statement should be considered in voting your shares. If you have already returned your proxy card or provided voting instructions, you do not need to take any action unless you wish to change your vote. Information on how to vote your shares and revoke already submitted proxies is available in the Proxy Statement.

     

    IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 22, 2025:

     

    The Proxy Statement is available for viewing, printing and downloading at www.scholarrock.com.

     

     

    Get the next $SRRK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRRK

    DatePrice TargetRatingAnalyst
    11/18/2025$42.00Outperform
    Wolfe Research
    10/9/2025$53.00Buy
    BofA Securities
    9/17/2025$45.00Overweight
    Barclays
    9/15/2025$51.00Outperform
    Leerink Partners
    8/21/2025$50.00Buy
    Jefferies
    7/30/2025$53.00Strong Buy
    Raymond James
    7/17/2025Overweight
    Cantor Fitzgerald
    11/26/2024$40.00 → $50.00Buy
    H.C. Wainwright
    More analyst ratings

    $SRRK
    SEC Filings

    View All

    Scholar Rock Holding Corporation filed SEC Form 8-K: Other Events

    8-K - Scholar Rock Holding Corp (0001727196) (Filer)

    12/2/25 7:00:38 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Scholar Rock Holding Corporation

    SCHEDULE 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/25 12:19:23 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Holding Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Scholar Rock Holding Corp (0001727196) (Filer)

    11/14/25 7:51:55 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Scholar Rock with a new price target

    Wolfe Research initiated coverage of Scholar Rock with a rating of Outperform and set a new price target of $42.00

    11/18/25 8:27:21 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BofA Securities initiated coverage on Scholar Rock with a new price target

    BofA Securities initiated coverage of Scholar Rock with a rating of Buy and set a new price target of $53.00

    10/9/25 8:29:07 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays initiated coverage on Scholar Rock with a new price target

    Barclays initiated coverage of Scholar Rock with a rating of Overweight and set a new price target of $45.00

    9/17/25 8:03:35 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Akkaraju Srinivas bought $18,807,352 worth of shares (500,439 units at $37.58) (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    10/7/25 8:59:19 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Akkaraju Srinivas bought $15,000,000 worth of shares (2,189,781 units at $6.85) (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    10/18/23 5:46:02 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Samsara Biocapital Gp, Llc bought $15,000,000 worth of shares (2,189,781 units at $6.85) (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    10/18/23 5:44:33 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF SCIENTIFIC OFFICER Qatanani Mo exercised 136,462 shares at a strike of $21.21 and sold $6,169,788 worth of shares (136,462 units at $45.21) (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    12/5/25 4:53:27 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Hallal David gifted 205,000 shares, decreasing direct ownership by 11% to 1,599,095 units (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    10/9/25 5:30:57 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Akkaraju Srinivas bought $18,807,352 worth of shares (500,439 units at $37.58) (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    10/7/25 8:59:19 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")), today announced that the company granted inducement equity awards covering an aggregate of 7,800 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 4,457 shares of common stock and inducement restricted stock units, covering an aggregate of 3,343 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is used excl

    12/13/25 10:57:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock to Present at Upcoming Investor Conferences

    Scholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in the following investor conferences: Citi 2025 Global Healthcare Conference: Scholar Rock is scheduled to participate in a fireside chat at 1:00 p.m. ET on Wednesday, December 3, 2025 in Miami, FL. 8th Annual Evercore Healthcare Conference: Scholar Rock is scheduled to participate in a fireside chat at 8:20 a.m. ET

    11/18/25 8:00:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights

    Completed constructive and collaborative in-person Type A meeting with U.S. Food and Drug Administration (FDA) on November 12th for apitegromab biologics license application (BLA) for the treatment of children and adults with spinal muscular atrophy (SMA) Catalent Indiana, LLC (part of Novo Nordisk) participated in the Type A meeting in person and presented the progress made in implementing the remediation plan; confirmed to FDA that the site is on-track to be reinspection ready by the end of this year Resubmission of BLA and U.S. launch following approval of apitegromab for children and adults with SMA anticipated in 2026 Timelines accelerated with additional apitegromab U.S. fil

    11/14/25 7:00:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Leadership Updates

    Live Leadership Updates

    View All

    Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer

    - Former Vice President and Global HR Head of Oncology and Pharma Development at Novartis brings extensive leadership experience focused on talent, culture, and diversity Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer. She will join the executive team, bringing more than 20 years of experience as a senior leader and strategic executive in the biotechnology and pharmaceutical industries. This press release features multimedia. View the full release here: https://www.businesswire.co

    8/16/21 4:05:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 9:00:58 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 7:24:55 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 1:22:38 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Financials

    Live finance-specific insights

    View All

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")), today announced that the company granted inducement equity awards covering an aggregate of 7,800 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 4,457 shares of common stock and inducement restricted stock units, covering an aggregate of 3,343 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is used excl

    12/13/25 10:57:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock to Present at Upcoming Investor Conferences

    Scholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in the following investor conferences: Citi 2025 Global Healthcare Conference: Scholar Rock is scheduled to participate in a fireside chat at 1:00 p.m. ET on Wednesday, December 3, 2025 in Miami, FL. 8th Annual Evercore Healthcare Conference: Scholar Rock is scheduled to participate in a fireside chat at 8:20 a.m. ET

    11/18/25 8:00:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights

    Completed constructive and collaborative in-person Type A meeting with U.S. Food and Drug Administration (FDA) on November 12th for apitegromab biologics license application (BLA) for the treatment of children and adults with spinal muscular atrophy (SMA) Catalent Indiana, LLC (part of Novo Nordisk) participated in the Type A meeting in person and presented the progress made in implementing the remediation plan; confirmed to FDA that the site is on-track to be reinspection ready by the end of this year Resubmission of BLA and U.S. launch following approval of apitegromab for children and adults with SMA anticipated in 2026 Timelines accelerated with additional apitegromab U.S. fil

    11/14/25 7:00:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care